Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Monday, April 13, 2026
Neomorph’s $100 Million Series B
ImageneBio’s $30 Million Private Placement
Friday, April 10, 2026
Oricell’s $110 Million Pre-IPO
Vivatides’s $54 Million Series A
Annovis’s $10 Million Public Offering
Thursday, April 9, 2026
Forte’s $150 Million Public Offering
Wednesday, April 8, 2026
ReAlta’s $150 Million Fund Raise
Sidewinder’s $137 Million Series B
Life Biosciences’s $80 Million Series D
Incyclix’s $5 Million Series B
Polyrizon’s $3 Million Registered Direct and Private Placement
Tuesday, April 7, 2026
Kiora’s $24 Million Private Placement
Monday, April 6, 2026
Apnimed’s $150 Million Debt Financing
Stipple’s $100 Million Series A
Friday, April 3, 2026
Acurion’s $4 Million Seed Round
Thursday, April 2, 2026
Adagene’s $70 Million Public Offering
INOVIO’s $17 Million Public Offering…More
Entera’s $10 Million Private Placement
OS’s $5 Million Registered Direct Offering
FibroBiologics’s $3 Million Public Offering
Wednesday, April 1, 2026
Cyclerion’s $380 Million Merger with Korsana Biosciences
Celldex’s $300 Million Public Offering
Aprea’s $30 Million Private Placement
Hoth’s $2 Million Registered Direct Offering
Apollomics’s $2 Million Bridge Financing
NewcelX’s $1 Million Equity Financing
Gilead’s Acquisition of Arcellx
Tuesday, March 31, 2026
Ambrosia’s $100 Million Series B
ImmunityBio’s $75 Million Royalty Financing
ONCOMATRYX’s $67 Million Venture Financing
SCYNEXIS’s $40 Million Private Placement
TippingPoint’s $4 Million Seed Round
Semarion’s $4 Million Fund Raise
VolitionRx Secures $2 Million Grant
Lilly’s Acquisition of Centessa Pharmaceuticals
Biogen Acquisition of Apellis Pharmaceuticals
Monday, March 30, 2026
Connect’s $20 Million Private Placement
Quince’s $16 Million Debt Financing
Artelo’s $11 Million Private Placement
Aurinia’s Acquisition of Kezar Life Sciences
Friday, March 27, 2026
Otsuka’s $700 Million Acquisition of Transcend Therapeutics
OnKure’s $150 Million Private Placement
Zenas’s $200 Million Public Offerings and Debt Financing
Vor’s $75 Million Private Placement
Stratum’s $2 Million Seed Round
Thursday, March 26, 2026
Pinnacle’s $89 Million Series B
Terrestrial’s $50 Million Series C
Wednesday, March 25, 2026
Merck’s $6.7 Billion Acquisition of Terns Pharmaceuticals
Endogenex ‘s $50 Million Series C
Tuesday, March 24, 2026
Gilgamesh’s $60 Million Series A
EpiFrontier’s $32 Million Grant
Karyopharm’s $30 Million Private Placement
Turn’s $25 Million Debt Financing
Rybodyn’s $10 Million Seed Round
RenovoRx’s $10 Million Private Placement…More
Outlook’s $5 Million Public Offering
Sernova’s $2 Million Private Placement
Monday, March 23, 2026
Reviva’s $10 Million Public Offering…More
Tempest’s $6 Million Private Placement
Friday, March 20, 2026
Earendil’s $787 Million Venture Financing
Hansa’s $30 Million Debt Financing
Bioxytran’s $1 Million Private Placement
Thursday, March 19, 2026
SAB’s $85 Million Public Offering
Humacyte’s $20 Million Registered Direct Offering
Azitra’s $10 Million Private Placement
Wednesday, March 18, 2026
Crossbow’s $77 Million in Series B
Excalipoint’s $69 Million Seed Round
Ovid’s $60 Million Private Placement
Serina’s $30 Million Private Placement
Kupando’s $27 Million Series A
Tuesday, March 17, 2026
Monday, March 16, 2026
CytomX’s $250 Million Public Offering
Alto’s $120 Million Private Placement
Unnatural’s $45 Million Series B
Acumen’s $36 Million Private Placement
Outlook’s $18 Million Debt Financing
Friday, March 13, 2026
Indivior’s $450 Million Debt Financing
Equillium’s $35 Million Private Placement
Cinclus’s $32 Million Venture Financing
Thursday, March 12, 2026
Dianthus’s $719 Million Public Offering…More, More
Wednesday, March 11, 2026
CRISPR’s $550 Million Debt Financing…More
Longeveron’s $30 Million Private Placement
Tuesday, March 10, 2026
Xenon’s $650 Million Public Offering
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)
collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.